Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat Plus Hydroxychloroquine vs Regorafenib in Refractory mCRC
NCT02316340Phase 2Completed
- Sponsor
- UT Health San Antonio
- Start
- Feb 2015
- Primary completion
- Mar 2018
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat, hydroxychloroquine in metastatic colorectal cancer (mCRC), sponsored by UT Health San Antonio. Started Feb 2015; status: completed.
02
Drugs
vorinostathydroxychloroquine
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02316340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02316340.